Congress expanding Mylan inquiry to determine if there was Medicaid fraud

Congress expanding Mylan inquiry to determine if there was Medicaid fraud-washingtonpost: Congress is not done with Mylan. Top senators angered by the exorbitant cost of the EpiPen, produced by Mylan, are expanding their inquiry to federal health regulators to discern whether the drug company knowingly and improperly paid state Medicaid programs less than it should have.